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Abstract
Background: Helicobacter pylori (HP) infection is associated with reduced lung function and systemic inflammation
in chronic obstructive pulmonary disease (COPD) patients. Azithromycin (AZ) is active against HP and reduces the
risk of COPD exacerbation. We determined whether HP infection status modifies the effects of AZ in COPD patients.
Methods: Plasma samples from 1018 subjects with COPD who participated in the Macrolide Azithromycin (MACRO)
in COPD Study were used to determine the HP infection status at baseline and 12 months of follow-up using a
serologic assay. Based on HP infection status and randomization to either AZ or placebo (PL), the subjects were
divided into 4 groups: HP+/AZ, HP-/AZ, HP+/PL, and HP-/PL. Time to first exacerbation was compared across the 4
groups using Kaplan-Meier survival analysis and a Cox proportional hazards model. The rates of exacerbation were
compared using both the Kruskal-Wallis test and negative binomial analysis. Blood biomarkers at enrolment and at
follow-up visits 3, 12, and 13 (1 month after treatment was stopped) months were measured.
Results: One hundred eighty one (17.8%) patients were seropositive to HP. Non-Caucasian participants were nearly
three times more likely to be HP seropositive than Caucasian participants (37.4% vs 13.6%; p < 0.001). The median
time to first exacerbation was significantly different across the four groups (p = 0.001) with the longest time in the
HP+/AZ group (11.2 months, 95% CI; 8.4–12.5+) followed by the HP-/AZ group (8.0 months, 95% CI; 6.7–9.7). Hazard
ratio (HR) for exacerbations was lowest in the HP+/AZ group after adjustment for age, sex, smoking status, ethnicity,
history of peptic ulcer, dyspnea, previous hospital admission, GOLD grade of severity, and forced vital capacity
(HR, 0.612; 95% CI, 0.442–0.846 vs HR, 0.789; 95% CI, 0.663–0.938 in the HP-/AZ group). Circulating levels of soluble
tumor necrosis factor receptor-75 were reduced only in the HP+/AZ group after 3 months of AZ treatment
(−0.87 ± 0.31 μg/L; p = 0.002); levels returned to baseline after discontinuing AZ.
Conclusions: AZ is effective in preventing COPD exacerbations in patients with HP seropositivity, possibly by
modulating TNF pathways related to HP infection.
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Background
Persistent systemic inflammation affects ~15 to 20% of
patients with chronic obstructive pulmonary disease
(COPD), which in turn is associated with an increased
risk of exacerbations and mortality [1]. The etiology for
this persistent inflammation in COPD, however, is
largely a mystery [2]. There is growing evidence that the
gastrointestinal tract is a major modulator and driver of
inflammation and that the gut-lung axis may be per-
turbed in COPD [3, 4]. Previous studies have reported
an increased prevalence of Helicobacter pylori (HP) in-
fection in patients with COPD [5]. Using serum samples
from the Lung Health Study (LHS), we recently showed
that ~18% of patients in that cohort had serologic evi-
dence for HP infection, which was associated with sys-
temic inflammation and reduced lung function [6]. HP
infection may promote persistent low-grade inflamma-
tion by up-regulating antigenic stimulation in mucosal
surfaces and by skewing the lymphocyte response to-
wards a T helper (Th) lymphocyte 1 bias [7–9].
Interestingly, azithromycin (AZ), which is being in-
creasingly used to prevent exacerbations in COPD has
bactericidal activity against HP both in vitro and in vivo
[10, 11]. In general, the immunomodulatory effects of
AZ preferentially attenuate Th1 (rather than Th2) re-
sponses [12, 13] and decrease tumor necrosis factor
(TNF)-α production by human monocytes [14]. How-
ever, whether HP modifies the effectiveness of AZ in
patients with COPD is unknown. Using data from the
MACRO (MACROlide azithromycin to prevent COPD
exacerbations) Study [15], we determined the impact of
HP infection status on the beneficial effects of AZ in
preventing exacerbations in patients with COPD.
Methods
Details of the MACRO Study design and results have been
published previously [15]. The study cohort consisted of
1142 subjects with COPD who were randomized either to
azithromycin (AZ, 250 mg) or a placebo tablet (PL) taken
daily for 12 months in addition to usual care. The primary
outcome of interest was the time to first exacerbation of
COPD, defined as a complex of respiratory symptoms (in-
creased or new onset) consisting of two or more of the fol-
lowing: cough, sputum, wheezing, dyspnea, or chest
tightness with a duration of at least three days and requir-
ing treatment with antibiotics or systemic steroids or both
in combination [15]. At the time of study entry, all sub-
jects had to have been free of an acute exacerbation of
COPD (AECOPD) for at least 4 weeks prior to
randomization. Subjects were monitored for AECOPDs at
clinic visits, which occurred at 3-month intervals, and by
monthly telephone contact between each clinic visit.
For the current study, we used blood samples that were
available from 1018 subjects to determine the prevalence
of HP seropositivity (HP+ or HP-). Plasma samples, col-
lected at enrollment and at the 12 month visit, were used
to measure concentrations of immunoglobulin G (IgG) to
HP cytotoxin-associated gene A (CagA) antigen using a
commercially available ELISA kit (DRG Diagnostics,
GmbH, Marburg, Germany) according to the manufac-
turer’s protocol. Samples with values greater than 18 DU/
mL were regarded as positive for HP infection (HP+).
Values lower than 18 DU/mL were considered HP nega-
tive (HP-) [6]. Using this cutoff value, seroconverters were
defined as patients who were seronegative at enrollment
but became seropositive at the 12 month visit. Serorever-
ters were defined as subjects who were seropositive at en-
rolment but became seronegative at the 12 month visit. A
significant reduction in HP antibody was defined as a
≥50% decrease in IgG antibody levels over 12 months [16,
17]. Fifteen patients failed to come in for follow-up visits
and were excluded from the remaining analyses. Thus,
1003 subjects were used to evaluate the time to first ex-
acerbation and rate of exacerbation during the 1 year.
These 1003 patients were further divided into 4 groups
based on their initial HP status and randomization to AZ
or PL treatment (HP+/AZ, HP-/AZ, HP+/PL, HP-/PL).
To determine whether AZ and HP status modified
common biomarkers of systemic inflammation, we related
these parameters to plasma levels of C-reactive protein
(CRP) and soluble tumor necrosis factor receptor-75
(sTNFR75), which had been previously measured at base-
line and at the 3, 12 and 13 (1 month after treatment dis-
continuation) month visits in the MACRO participants.
The details of these measurements have been previously
reported [18]. The MACRO study received approval from
each participating institution’s local research ethics board
and the present study received approval from the Univer-
sity of British Columbia/Providence Health Care Research
Ethics Committee (Approval No. H11-00786).
Statistical analyses
Exacerbation-free survival was assessed using Kaplan-
Meier curves stratified by HP serostatus and AZ use, and
the groups were compared by a log-rank test. Bootstrap
methods were used to generate the confidence intervals
(CIs) for median time to the first exacerbation [19]. Pair-
wise comparisons were performed to determine the differ-
ences in survival rate between each pair of groups using a
generalized Wilcoxon test (Breslow test). A Cox propor-
tional hazards regression was performed to adjust for
potential confounders including age, sex, smoking status,
ethnicity, history of peptic ulcer, dyspnea, previous
hospital admission for COPD during past year, Global
Initiative for Chronic Obstructive Lung Disease (GOLD)
grade of severity of airflow limitation, and forced vital
capacity (FVC) on these relationships using HP-/PL as the
reference group. The rates of exacerbation were determined
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by dividing the number of acute exacerbations by the
person-years of follow-up, and were compared using both
the Kruskal-Wallis test and negative binomial analysis.
We used paired t-tests to compare HP antibody levels at
baseline vs. the 12 month follow-up in each of the 4
groups. Plasma concentrations of CRP and sTNFR75
levels were log-transformed and paired t-tests were used
to determine the differences in concentrations between
samples collected at enrollment and at the 3, 12, and
13 month visits within the 4 groups. All statistical analyses
were performed using SPSS version 21.0 for Windows
(IBM Corp., Armonk, NY, USA) and R version 3.2.2
(available from https://www.r-project.org).
Results
Characteristics of the study subjects based on HP status
Plasma samples from 1018 subjects at enrollment were
analyzed to determine the prevalence of HP seropositiv-
ity; 181 patients (17.8%) had positive titres. HP sero-
prevalence was substantially lower among Caucasian
than non-Caucasian subjects (13.6% vs 37.4%; p < 0.001),
even though the history of peptic ulcer was similar
between the two groups (13.8% vs 13.7%; p = 0.985 by
Chi-square test). After excluding 15 patients without
follow-up visits, the baseline characteristics of the
remaining 1003 patients according to HP status are
summarized in Table 1. In the HP seropositive group,
the proportion of a peptic ulcer history was higher and
FVC (%) was lower as compared to HP seronegative
group. The patient characteristics stratified by HP status
and treatment (HP+/AZ, HP-/AZ, HP+/PL, or HP-/PL)
can be found in Additional file 1: Table S1. There were
no significant differences in age, sex, smoking status,
pack years of smoking, dyspnea grade, hospital admis-
sion for COPD or the use of systemic steroids and/or
antibiotics past year, lung function, GOLD grade of
severity of airflow limitation, or baseline levels of
biomarkers (CRP and sTNFR75) between the 4 groups.
The proportion of a peptic ulcer history was higher in
HP seropositive groups (HP+/AZ and HP+/PL) than HP
seronegative groups (HP-/AZ and HP-/PL).
Time to first exacerbation in relation to HP status and
azithromycin use
The median time to first exacerbation was the longest in
the HP+/AZ group (11.2 months, 95% CI; 8.4–12.5+),
followed by the HP-/AZ group (8.0 months, 95% CI; 6.7–
9.7), the HP+/PL group (7.5 months, 95% CI; 4.9–8.8) and
Table 1 Characteristics of Helicobacter pylori positive and negative patients
H. pylori positive, n = 179 H. pylori negative, n = 824 p-value*
Age, years 66.2 ± 8.5 65.3 ± 8.7 0.18
Male sex 118 (65.9) 485 (58.9) 0.08
Current smoker 36 (20.1) 175 (21.3) 0.73
Smoking history - Pack years 58.5 ± 32.5 58.3 ± 31.8 0.94
Ethnicity (Caucasian) 112 (62.6) 716 (86.9) <0.001
Peptic ulcer history 36 (20.1) 102 (12.4) 0.006
Dyspnea (MRC grade) 1.55 ± 0.89 1.53 ± 0.91 0.78
Hospitalization for COPD past year 80 (44.7) 423 (51.3) 0.11
FEV1, Liter 1.1 ± 0.5 1.1 ± 0.5 0.25
FEV1, % predicted 38.5 ± 15.1 39.9 ± 15.7 0.27
FVC, Liter 2.5 ± 0.8 2.7 ± 0.9 0.07
FVC, % predicted 67.8 ± 16.4 70.7 ± 18.3 0.049
FEV1/FVC % 42.5 ± 12.2 42.6 ± 12.8 0.97
GOLD grade, n (%) 0.65
II 42 (23.5) 216 (26.3)
III 75 (41.9) 344 (42.0)
IV 62 (34.6) 260 (31.7)
Baseline biomarker data
CRP (mg/L) 4.83 ± 3.89 4.91 ± 3.87 0.80
sTNFR75 (μg/L) 8.79 ± 4.41 8.71 ± 4.87 0.85
Data are presented as means ± standard deviation or absolute number (%)
MRC medical research council, FEV1 forced expiratory volume in one second, FVC forced vital capacity, GOLD Global Initiative for Chronic Obstructive Lung Disease,
CRP C-reactive protein, sTNFR75 soluble tumor necrosis factor receptor-75
*Unpaired t-test or Chi-square test
The results of FEV1, FVC, and FEV1/FVC are post-bronchodilator values
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the HP-/PL group (5.7 months, 95% CI; 4.5–7.2) with a
significant difference across these 4 groups by a log-rank
test (p = 0.001; Fig. 1). Pair-wise comparisons were per-
formed across the 4 groups using a generalized Wilcoxon
test (Breslow test), which showed significant differences in
survival function for the time to first exacerbation between
the HP+/AZ group and the HP-/AZ group (p = 0.04); the
HP+/PL group (p = 0.006) and the HP-/PL group (p =
0.001); and between the HP-/AZ and the HP-/PL groups
(p = 0.02). A Cox proportional hazards regression was per-
formed to investigate the relationship between the 4 groups
in regards to the time to first exacerbation. Hazard ratio
(HR) for the time to first exacerbation was the lowest in the
HP+/AZ group after adjusting for age, sex, smoking status,
ethnicity, history of peptic ulcer, dyspnea, previous hospital
admission for COPD during past year, GOLD grade of se-
verity of airflow limitation, and FVC (HR, 0.612; 95% CI,
0.442–0.846; p = 0.003 vs HR, 0.789; 95% CI, 0.663–0.938;
p = 0.007 in the HP-/AZ group vs HR, 1.096; 95% CI,
0.832–1.442; p = 0.52 in the HP+/PL group vs HR, 1 in the
reference group [HP-/PL]). The rates of exacerbation
per patient-year were 1.21, 1.54, 1.73, and 1.85, respect-
ively (p = 0.007 by Kruskal-Wallis test; Additional file 1:
Table S2). The HP+/AZ group had a 31% lower exacer-
bation rate compared to the HP-/PL group (p = 0.02),
whereas the HP-/AZ group had a 14% lower exacerba-
tion compared to the HP-/PL group (p = 0.08).
Change in HP status and antibody levels over 1 year
We also measured HP antibodies in plasma collected at the
12 month visit in 643 subjects. The HP seroprevalence
changed from 17.8% (181/1018) to 16.6% (107/643) after
1 year.
Seroconversion rates and changes in antibody
concentrations
Of the 530 COPD patients at risk of acquiring HP infec-
tion (i.e. seronegative at the baseline plasma measure-
ment), 21 (8 from the HP-/AZ group and 13 from the
HP-/PL group) became seropositive, resulting in an an-
nual seroconversion rate of 4.0% (Table 2). Overall, there
was a significant increase in HP antibody titres over
1 year of follow-up among participants in the HP-/PL
group (3.21 ± 1.56 DU/ml; mean ± standard error of
mean; p = 0.041; Fig. 2). In contrast, the HP antibody
titres did not change significantly during follow-up in
the HP-/AZ group (1.38 ± 1.07 DU/ml ; p = 0.198).
Seroreversion rates and changes in antibody concentrations
The seroreversion rate was not statistically different be-
tween AZ and PL use group (20.4% vs 27.1%; p = 0.401
by Chi-square test; Table 2). Of the 113 COPD patients
who were IgG seropositive at study entry, 27 (11 from
the HP+/AZ group, 16 from the HP+/PL group) became
seronegative, resulting in an annual seroreversion rate of
Fig. 1 Proportion of participants free from acute exacerbations of chronic obstructive pulmonary disease (COPD). AZ, Azithromycin; PL, Placebo;
HP, Helicobacter pylori. Pair-wise comparisons between each group showed significant differences in the time to first exacerbation between: The
HP+/AZ group versus HP-/AZ group (11.2 months, 95% CI; 8.4–12.5+ vs 8.0 months, 95% CI; 6.7–9.7; p = 0.040); The HP+/AZ group versus the HP
+/PL group (7.5 months, 95% CI; 4.9–8.8; p = 0.006); and The HP+/AZ group versus the HP-/PL group (5.7 months, 95% CI; 4.5–7.2; p = 0.001). There
was a significant difference between the HP-/AZ and the HP-/PL groups (p = 0.020). The remaining pair-wise comparisons were not
statistically significant
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23.8% (Table 2); 25 patients (22.1%) demonstrated at
least a 50% reduction in their baseline IgG antibody
titres at 12 months (Additional file 1: Table S3). In the
HP+/AZ group, HP antibody titres decreased signifi-
cantly during follow-up (−35.42 ± 9.41 DU/ml; p < 0.001;
Fig. 2). Patients in the HP+/PL group also experienced a
significant decline in HP titres during this time (−45.91
± 11.83 DU/ml; p < 0.001).
Serial change in CRP and sTNFR75 in relation to baseline
HP status and treatment
Plasma CRP and sTNFR75 levels were available for 1001
of the 1003 subjects (99.8%) at baseline and 859 (85.6%),
719 (71.7%), and 697 (69.5%) subjects at 3, 12, and
13 months of follow-up, respectively. We analyzed the
mean (± SEM) changes in the log-transformed CRP or
sTNFR75 levels within subjects from baseline to 3, 12,
and 13 months using paired t-tests (Fig. 3). CRP de-
creased significantly after 3 months in the HP-/AZ
group (−0.33 ± 0.18 mg/L; p = 0.047) and in the AZ use
group (−0.34 ± 0.16 mg/L; p = 0.02; Fig. 3 and Additional
file 1: Table S4). After discontinuing AZ at 12 months,
CRP returned to baseline levels at 13 months in these
groups. In terms of sTNFR75, only the HP+/AZ group
showed a significant decrease at 3 months (−0.87 ±
0.31 μg/L; p = 0.002; Fig. 3, Table 3) and the levels
returned to baseline levels after discontinuing AZ. The
differences in CRP and sTNFR75 concentrations be-
tween the other time points and baseline levels were not
significant.
Discussion
The present study is the first to evaluate the effect of azi-
thromycin on COPD exacerbations according to serosta-
tus for Helicobacter pylori (HP). The most important
findings were that approximately 18% of patients with
COPD in the MACRO Study were seropositive for HP
and that these individuals experienced the largest reduc-
tion in the risk for exacerbation from chronic prophylactic
AZ therapy. AZ therapy in these patients was associated
with a significant decline in plasma sTNFR75 levels, but
not with seroreversion rate as compared to PL use group.
Together, these data suggest that AZ therapy alone prob-
ably does not eradicate HP infection but may have a
significant immunomodulatory role that mitigates the risk
of exacerbations in HP seropositive individuals.
It is now well-established and accepted that chronic
prophylactic therapy with macrolides such as AZ re-
duces the risk of exacerbations in patients with COPD.
However, many national and international guidelines
and strategic documents avoid strong endorsement for
their use because of the concerns about long-term side
effects, including decreased hearing acuity, arrhythmo-
genesis, and the possibility of promoting widespread
antimicrobial resistance [20, 21]. Given these concerns,
it would be highly desirable to develop biomarkers that
can identify patients who would benefit the most from
these therapies. In a post hoc analysis of the MACRO
data, Han and colleagues showed that the benefits of AZ
were greatest in ex-smokers, older patients, and subjects
with mild COPD. However, in their study, reductions in
exacerbations were still seen in younger patients and
those with higher GOLD grades of airflow limitation,
particularly for exacerbations that required treatment
with antibiotics and steroids [22]. We extend these find-
ings by demonstrating that the risk of exacerbation is re-
duced by 39% with AZ in patients who were seropositive
to HP (versus only 21% in HP- individuals; p = 0.04).
Table 2 HP status at 12 months according to baseline HP status
and treatment in 643 COPD patients
Baseline HP status
and treatment
HP status after 12 months Total
Negative n = 536 Positive n = 107
HP-/AZ 269 (97.1%) 8 (2.9%) 277 (100%)
HP-/PL 240 (94.9%) 13 (5.1%) 253 (100%)
Total (HP-) 509 (96.0%) 21 (4.0%) 530 (100%)
HP+/AZ 11 (20.4%) 43 (79.6%) 54 (100%)
HP+/PL 16 (27.1%) 43 (72.9%) 59 (100%)
Total (HP+) 27 (23.8%) 86 (76.2%) 113 (100%)
The percentages in the table were calculated row-wise
HP Helicobacter pylori, AZ azithromycin, PL placebo
Fig. 2 Individual IgG antibody titres to H. pylori (HP) CagA antigen in
plasma of COPD patients at 0 (baseline) and 12 months. AZ,
Azithromycin; PL, Placebo. The horizontal lines denote arithmetic
means for individual groups. The differences in antibody
concentrations within an individual patient between two time points
were compared using a paired t-test. During follow-up, there was a
significant decrease in antibody level from baseline (mean ± SEM) in
both the HP+/AZ group (−35.42 ± 9.41; p < 0.001) and the HP+/PL
group (−45.91 ± 11.83; p < 0.001) over the year. There was no
significant increase in antibody level from baseline in the HP-/AZ group
(1.38 ± 1.07; p = 0.198). In contrast, there was a significant increase in
the HP-/PL group (3.21 ± 1.56; p = 0.041)
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Interestingly, using the same cohort, Woodruff et al.
found that a decline in sTNFR75 concentrations over
3 months identified COPD patients who benefited from
AZ therapy [18]. We extend these findings by demonstrat-
ing that the largest (and most significant) reductions in
circulating sTNFR75 levels after 3 months were observed
in HP+ patients who were treated with AZ (N = 76; −0.87
± 0.31 μg/L; p = 0.002), followed by ex-smokers (N = 360;
−0.17 ± 0.24 μg/L; p = 0.03; Table 3). However, AZ therapy
was also beneficial in HP seronegative individuals
(although the impact was less striking than those who
were HP+), suggesting that the mechanisms and pathways
by which AZ mitigates exacerbations in COPD are diverse
and complicated and extend beyond those with HP
seropositivity.
In contrast to sTNFR75, CRP concentration at 3 months
was significantly reduced in the AZ group (N = 432; −0.34
± 0.16 mg/L; p = 0.02; Fig. 3, Additional file 1: Table S4)
and not reduced in the HP+/AZ group (N = 76; −0.40 ±
0.38 mg/L; p = 0.17), suggesting that potential mechanisms
for the reduction in CRP levels include an anti-
inflammatory effect independent of the presence of HP in-
fection. Previously it was shown that there was an increase
in CRP level in mild to moderate COPD patients who
were stable and HP positive [6], whereas the present study
showed no significant difference in CRP or sTNFR75
levels between HP negative and positive COPD patients.
In addition, there was no significant difference in the time
to first exacerbation or rates of exacerbations between the
HP+/PL and HP-/PL groups (Fig. 1). We postulate that
this may reflect a selection bias towards inclusion of indi-
viduals prone to high systemic inflammation and exacer-
bation in the MACRO Study. It is likely that these
individuals had multiple drivers of exacerbations (not just
HP infection), which may have obscured the effects of HP
infection on systemic inflammation and the overall risk of
exacerbations in patients who received placebo during
follow-up. Consistent with this notion, the average CRP
Fig. 3 Serial change in blood biomarkers according to baseline H. pylori (HP) status and treatment. AZ, Azithromycin; PL, Placebo. The points and
error bars indicate the means and standard errors of change in C-reactive protein (CRP) and soluble tumor necrosis factor-75 (sTNFR75) levels
from baseline to 3, 12, and 13 months for each of the 4 groups. Paired t-tests were used to determine differences in biomarker concentrations
between the three time points and baseline levels. *p < 0.05, **p < 0.01. a CRP decreased significantly at 3 months in the HP-/AZ and AZ use
group. After stopping AZ at 12 months, CRP returned to baseline levels at 13 months. b sTNFR75 levels decreased significantly at 3 months only
in the HP+/AZ group and returned to baseline levels after stopping AZ
Table 3 Effect of azithromycin on changes in sTNFR75 levels at
3 months according to subgroups
Subgroup sTNFR75 level (μg/L) p-value*
N Baseline 3 months Difference
HP + 76 8.65 ± 0.50 7.78 ± 0.45 −0.87 ± 0.31 0.002
HP - 356 8.52 ± 0.24 8.63 ± 0.32 0.11 ± 0.25 0.64
Total 432 8.54 ± 0.22 8.48 ± 0.27 −0.06 ± 0.21 0.10
Ex-smoker 360 8.73 ± 0.24 8.56 ± 0.31 −0.17 ± 0.24 0.03
Smoker 89 8.10 ± 0.41 8.11 ± 0.43 0.01 ± 0.30 0.89
Age > 65 220 8.52 ± 0.29 8.46 ± 0.42 −0.06 ± 0.36 0.25
Age≤ 65 229 8.68 ± 0.31 8.48 ± 0.32 −0.20 ± 0.20 0.08
GOLD 2 120 9.07 ± 0.39 9.08 ± 0.67 0.01 ± 0.60 0.15
GOLD 3 183 8.68 ± 0.32 8.49 ± 0.34 −0.19 ± 0.22 0.29
GOLD 4 145 8.12 ± 0.40 7.86 ± 0.40 −0.26 ± 0.27 0.19
Data are presented as means ± standard errors of the mean
sTNFR75 soluble tumor necrosis factor-75, GOLD Global Initiative for Chronic
Obstructive Lung Disease, HP Helicobacter pylori
*Paired t-tests on log-transformed data
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values in the MACRO Study participants were signifi-
cantly higher compared to those of previous studies,
which had enrolled stable COPD patients [1, 6].
Seropositivity to HP, and annual rates of seroconver-
sion and reversal, is not well-known in patients with
COPD. Our previous study using serum samples from
the lung health study (LHS) and ELISA plates coated
with CagA protein demonstrated a cross-sectional
prevalence of HP seropositivity of 17.6% [6]. However,
this study was limited in that serum samples were col-
lected in the 1990’s before the widespread availability of
triple therapy for HP eradication. Here, using a more
contemporaneous cohort (MACRO), we report a similar
HP seropositivity rate despite advances in diagnosis and
availability of effective therapies for HP. It is also notable
that in the MACRO Study we found a substantially
higher rate of HP seropositivity among non-Caucasian
subjects than Caucasian subjects (37.4% vs 13.6%). Con-
sidering that approximately 60% of Western HP strains
demonstrate CagA antigen expression, these data are
consistent with results from the National Health and
Nutrition Examination Survey (1999–2000) conducted
in US adults, which used HP antigen coated ELISA
plates (Wampole Laboratories, Princeton, New Jersey)
and reported a higher age-standardized seroprevalence
of HP in Mexican Americans (64.0%) and non-Hispanic
blacks (52.0%) compared with Caucasians (21.2%) [23].
Despite the difference of HP seropositivity between
Caucasian and non-Caucasian subjects, the proportion
with a peptic ulcer history was similar between two
groups in our study, suggesting that additional studies
would be required to find the mechanism to explain the
disparities among ethnicities who may have different
dietary cultures and diverse intestinal microbiota com-
munities. AZ may have differential effect on the intes-
tinal microbiota including helicobacter genus. The
overall annual seroconversion rate in our study subjects
was 4% with rates numerically lower in the AZ group
compared to the PL group. A 4% annual seroconversion
rate in our study subjects is higher than previously re-
ported in high-income countries (~0.01–1% per year in
the general adult population) [24–27]. A previous study
suggests that older age and smoking are associated with
an increased risk of HP [28], possibly due to immune
dysregulation and senescence. The overall annual serore-
version rate in our study subjects was 23.8% (27/113)
and the rate between the PL and AZ groups was not sta-
tistically different. In line with the high rate of serocon-
version in our study subjects, seroreversion rate was
even higher than other studies performed in the general
adult population [24, 27, 29]. Kuipers et al. documented
that HP positivity reverted in only 3 of 56 subjects in the
absence of specific antimicrobial therapy over 11 years
[25]. Since the many of our study subjects were using
home oxygen therapy and some had advanced COPD,
they experienced frequent exacerbations leading to re-
peated exposures to antibiotics and steroids during the
study period.
Importantly, in the HP-/AZ group, there was no sig-
nificant increase in HP antibody titres over the 12 month
period; by contrast, there was a significant increase in
HP antibody titres in the HP-/PL group, suggesting that
AZ use prevented significant increases in HP antibody
levels in HP- patients. Moreover, although AZ has some
in vitro and in vivo activity against HP, we did not find a
significant difference in the rate of seroreversion
between the PL and AZ groups. We also used ≥50% de-
cline in titres at 12 months of follow-up compared to
baseline levels as indirect evidence for HP eradication
[16, 17] since absolute antibody titres remain in the
positive range for 1 to 4 years after successful eradica-
tion [30, 31]. Interestingly, HP+ patients who experi-
enced at least one exacerbation during the 12 month
follow-up were more likely to demonstrate a ≥50% re-
duction in HP titres during follow-up compared to those
who did not experience any exacerbations (30.1% eradica-
tion rate vs 7.5%; p = 0.006; Additional file 1: Table S3).
Again, this raises the possibility that antibiotic exposure
during exacerbations may have played a significant role in
decreasing antibody levels. Consistent with this hypoth-
esis, a previous study showed that children who had been
treated with antibiotics demonstrated lower risk of HP
infection compared with those who had never been
treated with antibiotics (12.5% vs 30%) [32]. Together,
these data suggest that although AZ monotherapy prob-
ably does not prevent new HP infection or eradicate exist-
ing infection, it likely downregulates the host’s immune
responses [10, 11] and dampens macrophage responses
and Th1 immunity related to TNF pathways [12–14].
Limitations of the study
There were several limitations that should be noted in the
current study. First, we do not know how many patients
with an HP infection developed resistance to macrolides
after 1 year of AZ exposure. HP readily becomes resistant
to macrolides when given alone, and short-term AZ
monotherapy is not considered sufficient for HP eradica-
tion [33–35]. Moreover, we had no available data on the
presence of gastric diseases or symptoms, or signs that
could indicate active HP infection, though we did deter-
mine HP serostatus by using the CagA antigen, which is a
well-known virulent strain causing more severe gastrodu-
odenal disease [36]. However, to date, AZ monotherapy
for COPD patients with HP seropositivity cannot be advo-
cated without further study. For those who are seroposi-
tive, HP infection should be further explored and treated
with the appropriate triple therapy regimen. Second, we
did not have detailed information regarding the use of
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prescription or over-the-counter antisecretory drugs,
which may be responsible for prevention (or even treat-
ment) of COPD exacerbations in patients with gastric
symptoms and could have affected HP antibody levels in
our patient population. Third, the use of antibiotics or ste-
roids other than AZ could also have affected HP titres in
our study subjects. Fourth, the present study used a retro-
spective design and did not focus on the potential patho-
genic mechanisms underlying the association between HP
infection and COPD exacerbation. It is well known that
HP can stimulate the release of a variety of pro-
inflammatory cytokines, including interleukin-1 (IL-1),
IL-8 and TNF-α [37, 38] and these cytokines are also
thought to be involved in the pathogenesis of COPD [39,
40]. Therefore, HP infection might play a pro-
inflammatory role and be a cofactor in the pathogenesis of
COPD exacerbation. Finally, although we demonstrated
differential effect of AZ therapy on the risk of exacerba-
tion in HP seropositive COPD patients, the mechanism by
which this occurs is unknown. We posit that AZ sup-
presses (but not fully eradicates) HP infection, which in
turn, may downregulate the TNF pathway. Experimental
studies will be required in the future to tease out the full
mechanisms to explain the beneficial effects of AZ on HP
infection in COPD patients.
Conclusions
HP infection status was associated with differential
effects of AZ in COPD patients with frequent exacerba-
tions, highlighting the importance of evaluating HP sta-
tus in these group. Chronic AZ monotherapy suppressed
HP antibody levels after 1 year of treatment, but did not
significantly modify the rate of seroreversion in the HP+
group. The HP+/AZ group exhibited a decline in
sTNFR75 levels at 3 months. Patients who were HP
seropositive experienced a significantly greater protec-
tion against exacerbation from chronic AZ therapy than
those who were HP seronegative. A larger prospective
study is needed to definitively prove the benefit of eradi-
cation of HP with triple therapy in seropositive HP
patients with COPD, who frequently exacerbate.
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